ZHU:CA:TSX-BMO Equal Weight US Health Care (CAD)

COMMON STOCK | |

Last Closing

CAD 41.86

Change

0.00 (0.00)%

Market Cap

CAD 0.05B

Volume

534.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-07 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
TD-PFD:CA Toronto Dominion Bank Pref D

+0.14 (+0.58%)

CAD 169.00B
TD-PFI:CA Toronto-Dominion Bank Pref Ser..

+0.03 (+0.12%)

CAD 163.35B
ENB-PFV:CA Enbridge Inc Pref 5

-0.25 (-1.04%)

CAD 121.15B
ENB-PFA:CA Enbridge Inc Pref 9

+0.07 (+0.37%)

CAD 114.18B
ENB-PFC:CA Enbridge Inc Pref 11

+0.10 (+0.55%)

CAD 109.72B
ENB-PFG:CA Enbridge Inc Pref 15

+0.15 (+0.84%)

CAD 105.77B
ENB-PFU:CA Enbridge Inc Pref L

+0.20 (+0.90%)

CAD 87.65B
PPL-PFA:CA Pembina Pipeline Corp Pref Ser..

-0.14 (-0.59%)

CAD 9.59B
EIT-UN:CA Canoe EIT Income Fund

+0.11 (+0.75%)

CAD 2.61B
EVT:CA Economic Investment Trust Ltd

N/A

CAD 0.90B

ETFs Containing ZHU:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.22% N/A N/A 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.22% N/A N/A 32% F
Trailing 12 Months  
Capital Gain 3.10% N/A N/A 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.10% N/A N/A 28% F
Trailing 5 Years  
Capital Gain 34.34% N/A N/A 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.34% N/A N/A 58% F
Average Annual (5 Year Horizon)  
Capital Gain 6.59% N/A N/A 64% D
Dividend Return 6.59% N/A N/A 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.94% N/A N/A 61% D-
Risk Adjusted Return 50.90% N/A N/A 73% C
Market Capitalization 0.05B N/A N/A 27% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike